IF 5.9 4区医学

HLA Pub Date : 2024-10-27 DOI: 10.1111/tan.15729

Ahmed Gaballa, Anna Söderström, Nina Lundin, Torsten Eich

引用次数: 0

Genomic full-length sequence of the HLA-B*40:96 allele was identified by full length group-specific sequencing 通过全长组特异性测序，确定了 HLA-B*40:96 等位基因的基因组全长序列。

IF 5.9 4区医学

HLA Pub Date : 2024-10-27 DOI: 10.1111/tan.15686

Jiyong Zhou, Yi Duan, Ke Yuan, Zhihui Feng, Xiuxiang Liu

引用次数: 0

Detection of the Novel HLA-B*15:358 Allele by Sanger Dideoxy Nucleotide Sequencing 通过桑格双脱氧核苷酸测序检测新型 HLA-B*15:358 等位基因

IF 5.9 4区医学

HLA Pub Date : 2024-10-27 DOI: 10.1111/tan.15736

Jian-Ping Li, Xu Zhang, Feng-Qiu Lin, Xiao-Feng Li

引用次数: 0

Identification of the Novel Non-classical HLA-G*01:24:02 Allele by Next-Generation Sequencing 通过下一代测序鉴定新型非经典 HLA-G*01:24:02 等位基因。

IF 5.9 4区医学

HLA Pub Date : 2024-10-27 DOI: 10.1111/tan.15728

Yogini Mujumdar, Shramika Vasant Thakur, Deepika Baban Talge, Vikrant M. Bhor, Itta Krishna Chaaithanya

引用次数: 0

Characterisation of Two New HLA Alleles: HLA-C*04:524 and -DQB1*03:524 两个新 HLA 等位基因的特征：HLA-C*04:524 和 -DQB1*03:524

IF 5.9 4区医学

HLA Pub Date : 2024-10-27 DOI: 10.1111/tan.15726

Maria Loginova, Igor Paramonov

引用次数: 0

A new strategy for systematically classifying HLA alleles into serological specificities: Update and refinement 将 HLA 等位基因系统地划分为血清特异性的新策略：更新与完善。

IF 5.9 4区医学

HLA Pub Date : 2024-10-22 DOI: 10.1111/tan.15702

Kazutoyo Osoegawa, Kenneth Yim, Megan Jeracki, Tuan-Nghia Nguyen, Lin Wang, Andrew Cho, Rhidina David, Jellina Son, Arianne Mankey, Steven G. E. Marsh, Ketevan Gendzekhadze, Cathi Murphey, Marcelo A. Fernández Viňa

{"title":"A new strategy for systematically classifying HLA alleles into serological specificities: Update and refinement","authors":"Kazutoyo Osoegawa, Kenneth Yim, Megan Jeracki, Tuan-Nghia Nguyen, Lin Wang, Andrew Cho, Rhidina David, Jellina Son, Arianne Mankey, Steven G. E. Marsh, Ketevan Gendzekhadze, Cathi Murphey, Marcelo A. Fernández Viňa","doi":"10.1111/tan.15702","DOIUrl":"10.1111/tan.15702","url":null,"abstract":"HLA antigens were historically defined according to the unique reactivity pattern of cells expressing HLA molecules with distinctive clusters of allo-antisera and/or monoclonal antibodies. Subsequently, amino acid residues determining epitopes (DEP) in the HLA molecule were correlated with reactivity patterns. In current clinical practice, the presence of allo-antibodies is assessed using Luminex-based solid phase single antigen bead (SAB) assays for transplantation. Recently, novel antigens were proposed for HLA molecules with DEP patterns that do not match any serologically defined antigens recognised by the WHO Nomenclature Committee. To validate the antigens, mean fluorescence intensity values of SABs tested on >13,000 patients' sera were extracted from clinical databases and analysed by scatter plots using a linear regression model. We found that when two proteins were considered as the same antigen in the original study, for example, HLA-A*02:01 and -A*02:06, their correlation ranked among the highest values at each locus. In contrast, discrete asymmetric outliers were observed when there were different antigens, for example, HLA-A*30:01 and -A*30:02, allowing validation and confirmation of 20 novel antigens for HLA-A, -B, -C and -DR. The outliers were confirmed to be true or false by flow cytometric crossmatches. In addition to the previously defined residues for antigen assignments, findings suggest that further distinction should be made for common antigens by including the substitutions at residue 67 of HLA-B, 67 and 74 of -DR. These serologic analyses can be applied systematically to identify and confirm novel antigens. These developments will lead to designing optimal SAB panels and further improving virtual donor-specific antibodies assessment.","PeriodicalId":13172,"journal":{"name":"HLA","volume":"104 4","pages":""},"PeriodicalIF":5.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/tan.15702","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification of the Novel HLA-DQB1*03:01:01:69 Allele in a Candidate Bone Marrow Donor by Next Generation Sequencing 通过新一代测序鉴定候选骨髓捐献者的新型 HLA-DQB1*03:01:01:69 等位基因。

IF 5.9 4区医学

HLA Pub Date : 2024-10-22 DOI: 10.1111/tan.15741

Diamanto Kouniaki, Alexandra Tsirogianni

引用次数: 0

Identification of Candidate Immunodominant Epitopes and Their HLA-Binding Prediction on BK Polyomavirus Proteins in Healthy Donors 健康捐献者 BK 多瘤病毒蛋白上候选免疫显性表位的鉴定及其 HLA 结合预测

IF 5.9 4区医学

HLA Pub Date : 2024-10-22 DOI: 10.1111/tan.15722

Ana Gabriela Lara-de-León, Rut Mora-Buch, Ester Cantó, Cleofé Peña-Gómez, Francesc Rudilla

{"title":"Identification of Candidate Immunodominant Epitopes and Their HLA-Binding Prediction on BK Polyomavirus Proteins in Healthy Donors","authors":"Ana Gabriela Lara-de-León, Rut Mora-Buch, Ester Cantó, Cleofé Peña-Gómez, Francesc Rudilla","doi":"10.1111/tan.15722","DOIUrl":"10.1111/tan.15722","url":null,"abstract":"<div>\u0000 \u0000 BK polyomavirus infection is an important cause of graft loss in transplant patients, however, currently available therapies lack effectiveness against this pathogen. Identification of immunological targets for potential treatments is therefore necessary. The aim of this study was to predict candidates of immunodominant epitopes within four BK virus proteins (VP1, VP2, VP3 and LTA) using PBMCs from 44 healthy donors. We used the ELISpot epitope mapping method to evaluate the T-cell response, and HLA-peptide binding was predicted using the NetMHCpan algorithm. A total of 11 potential peptides were selected for VP1, 3 for VP2/VP3 and 13 for LTA. Greater reactivity was observed for VP1 and LTA proteins compared with VP2/VP3. Most of the peptides selected as potential immunodominant candidates were restricted towards several HLA class I and II alleles, with predominant HLA class I binding by computational predictions. Based on these findings, the sequences of the selected immunodominant epitopes candidates and their corresponding HLA restrictions could contribute to the optimisation of functional assays and aid in the design and improvement of immunotherapy strategies against BK virus infections.\u0000 </div>","PeriodicalId":13172,"journal":{"name":"HLA","volume":"104 4","pages":""},"PeriodicalIF":5.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Peptide Sharing Between CMV and Mismatched HLA Class I Peptides Promotes Early T-Cell-Mediated Rejection After Kidney Transplantation CMV与不匹配的HLA I类肽之间的肽共享会促进肾移植后T细胞介导的早期排斥反应。

IF 5.9 4区医学

HLA Pub Date : 2024-10-22 DOI: 10.1111/tan.15719

Emma T. M. Peereboom, Renato de Marco, Kirsten Geneugelijk, Jasvir Jairam, Frans M. Verduyn Lunel, Anna J. Blok, José Medina-Pestana, Maria Gerbase-DeLima, Arjan D. van Zuilen, Eric Spierings

{"title":"Peptide Sharing Between CMV and Mismatched HLA Class I Peptides Promotes Early T-Cell-Mediated Rejection After Kidney Transplantation","authors":"Emma T. M. Peereboom, Renato de Marco, Kirsten Geneugelijk, Jasvir Jairam, Frans M. Verduyn Lunel, Anna J. Blok, José Medina-Pestana, Maria Gerbase-DeLima, Arjan D. van Zuilen, Eric Spierings","doi":"10.1111/tan.15719","DOIUrl":"10.1111/tan.15719","url":null,"abstract":"Cytomegalovirus (CMV) infection is related to acute rejection and graft loss after kidney transplantation, though the underlying mechanism remains largely unknown. Some CMV strains produce a peptide that is identical to a peptide sequence found in the leader peptide of specific HLA-A and -C alleles. In this retrospective study of 351 kidney transplantations, we explored whether CMV-seropositive recipients without the VMAPRTLIL, VMAPRTLLL or VMAPRTLVL HLA class I leader peptide receiving a transplant from a donor with this peptide, faced an increased risk of T-cell-mediated rejection (TCMR) in the first 90 days after transplantation. An independent case–control cohort was used for validation (n = 122). The combination of recipient CMV seropositivity with the VMAPRTLIL peptide mismatch was associated with TCMR with a hazard ratio (HR) of 3.06 (p = 0.001) in a multivariable analysis. Similarly, the VMAPRTLLL peptide mismatch was associated with TCMR revealing a HR of 2.61 (p = 0.008). Transplantations featuring either a VMAPRTLIL or a VMAPRTLLL peptide mismatch had a significantly higher cumulative TCMR incidence (p < 0.0001), with the primary impact observed in the first 2 weeks post-transplantation. The findings could be validated in an independent cohort. Together, our data strongly suggest that CMV-positive recipients without an HLA peptide identical to a CMV peptide yet transplanted with a donor who does possess this peptide, have a significantly increased risk of early TCMR. Considering the prevention of such an leader peptide mismatch in these patients or adjusting immunosuppression protocols accordingly may hold promise in reducing the incidence of early TCMR.","PeriodicalId":13172,"journal":{"name":"HLA","volume":"104 4","pages":""},"PeriodicalIF":5.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/tan.15719","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Revolutionising High Resolution HLA Genotyping for Transplant Assessment: Validation, Implementation and Challenges of Oxford Nanopore Technologies' Q20+ Sequencing 彻底改变用于移植评估的高分辨率 HLA 基因分型：牛津纳米孔技术公司 Q20+ 测序的验证、实施和挑战。

IF 5.9 4区医学

HLA Pub Date : 2024-10-22 DOI: 10.1111/tan.15725

Naser El-Lagta, Linh Truong, Felipe Ayora, Fredrick Mobegi, Samuel Bruce, Patricia Martinez, Lloyd D'Orsogna, Dianne De Santis

{"title":"Revolutionising High Resolution HLA Genotyping for Transplant Assessment: Validation, Implementation and Challenges of Oxford Nanopore Technologies' Q20+ Sequencing","authors":"Naser El-Lagta, Linh Truong, Felipe Ayora, Fredrick Mobegi, Samuel Bruce, Patricia Martinez, Lloyd D'Orsogna, Dianne De Santis","doi":"10.1111/tan.15725","DOIUrl":"10.1111/tan.15725","url":null,"abstract":"The advent of third-generation sequencing (TGS) represents a significant shift in the field of genetic sequencing, enabling single-molecule sequencing to overcome limitations of short-read NGS platforms. Several studies have assessed the utilisation of TGS in HLA genotyping, though many of these studies have described the high error rate as an obstacle to achieving a robust and highly accurate HLA typing assay. In 2021, Oxford Nanopore Technologies (ONT) released the high-accuracy sequencing Kit 14 and the MinION flow cell model R10.4.1, which were reported to achieve sequencing accuracies up to 99%. The aim of this study was to validate this novel high-accuracy sequencing kit for HLA genotyping coupled with a full-gene HLA PCR assay. Comparison with historical data obtained using legacy flow cell models such as R9.4, R10.3 and R10.4 was also done to assess progressive improvement in sequencing performance with each sequential release. The workflow was validated based on data throughput, sequence quality and accuracy, and HLA genotyping resolution. An initial validation was performed using an internal reference panel of 42 samples representing common HLA allele groups, followed by an analysis of data obtained from 111 sequencing batch runs since the implementation, to assess assay performance and define quality control metrics to assess inter-run variability and monitor quality. Furthermore, challenges arising from MinION flow cell stability and use, and assessment of barcode contamination are discussed. The findings of this study highlight advantages of ONT sequencing kit 14/R10.4.1 for HLA genotyping and the implementation considerations for the routine diagnostic HLA laboratory.","PeriodicalId":13172,"journal":{"name":"HLA","volume":"104 4","pages":""},"PeriodicalIF":5.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/tan.15725","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HLA最新文献